The U.S. Food and Drug Administration has approved Leqembi Iqlik, a subcutaneous version of lecanemab, for weekly maintenance after the 18-month intravenous (IV) phase.Leqembi Iqlik is a subcutaneous autoinjector that delivers treatment in about 15 seconds for U.S. patients…

Read Full Article (External Site)